All chapters

Chapter 14

Soliris (Eculizumab): Discovery and Development

Eculizumab, marketed as ‘Soliris’ by Alexion Pharmaceuticals Inc., is a humanised, Fc-engineered (low effector function), IgG2/4 hybrid monoclonal antibody that blocks the activity of human complement factor C5. This activity enables eculizumab to potently suppress the pro-inflammatory and cytolytic effects of the terminal complement system, which are key factors in the pathology of the rare haemolytic disease paroxysmal nocturnal haemoglobinuria (PNH). This antibody therapeutic has become an important example of a potential therapeutic molecule that was originally developed for a series of common inflammatory diseases (rheumatoid arthritis, lupus, etc.), but was repurposed with great success to become a first-in-class complement inhibitor in the rare disease space.

Publication details

Print publication date
14 Aug 2014
Copyright year
2014
Print ISBN
978-1-84973-806-4
PDF eISBN
978-1-78262-420-2
ePub eISBN
978-1-78262-290-1

From the book series:
Drug Discovery